Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Gross Margin (2021 - 2025)

Historic Gross Margin for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to 90.47%.

  • Ascendis Pharma A's Gross Margin fell 14700.0% to 90.47% in Q4 2025 from the same period last year, while for Dec 2025 it was 86.92%, marking a year-over-year decrease of 8800.0%. This contributed to the annual value of 86.82% for FY2025, which is 10100.0% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Gross Margin is 90.47%, which was down 14700.0% from 89.54% recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Gross Margin ranged from a high of 100.0% in Q1 2021 and a low of 1.6% during Q4 2021
  • For the 5-year period, Ascendis Pharma A's Gross Margin averaged around 77.33%, with its median value being 83.63% (2023).
  • The largest annual percentage gain for Ascendis Pharma A's Gross Margin in the last 5 years was 760800bps (2022), contrasted with its biggest fall of -621900bps (2022).
  • Quarter analysis of 5 years shows Ascendis Pharma A's Gross Margin stood at 1.6% in 2021, then soared by 4769bps to 77.68% in 2022, then plummeted by -50bps to 39.06% in 2023, then surged by 135bps to 91.94% in 2024, then fell by -2bps to 90.47% in 2025.
  • Its Gross Margin was 90.47% in Q4 2025, compared to 89.54% in Q3 2025 and 80.1% in Q2 2025.